Cubist Systematic Strategies, LLC Celldex Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$35.22 - $51.88 $2.38 Million - $3.5 Million	67,434 New	67,434 $2.83 Million
Q2 2023 Aug 14, 2023	BUY	$30.29 - $38.28 $262,856 - $332,193	8,678 Added 311.93%	11,460 $388,000
Q1 2023 May 15, 2023	BUY	$34.78 - $47.43 $42,640 - $58,149	1,226 Added 78.79%	2,782 $100,000
Q4 2022 Feb 14, 2023	BUY	$27.78 - $45.38 $42,975 - $70,202	1,547 Added 17188.89%	1,556 $69,000
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $204 - $338	9 New	9 $0
Q2 2022 Aug 15, 2022	SELL	$20.5 - $37.33 $258,976 - $471,589	-12,633 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$27.64 - $39.32 $451,996 - $642,999	-16,353 Reduced 56.42%	12,633 $430,000
Q4 2021 Feb 14, 2022	BUY	$35.68 - $56.27 $252,007 - $397,435	7,063 Added 32.22%	28,986 $1.12 Million
Q3 2021 Nov 15, 2021	SELL	$28.95 - $55.99 $28,139 - $54,422	-972 Reduced 4.25%	21,923 $1.18 Million
Q2 2021 Aug 16, 2021	SELL	$20.71 - $35.37 $45,686 - $78,026	-2,206 Reduced 8.79%	22,895 $766,000
Q1 2021 May 17, 2021	BUY	$16.19 - $29.91 $406,385 - $750,770	25,101 New	25,101 $517,000

207

67.3M

1.69M

980K

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.23B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.